Vous êtes ici : Accueil   >   Actualités de l'institut : Bioconjugate Chem. [LSAMM]

Bioconjugate Chem. [LSAMM]

nov. 8 2018


A molecular theranostic agent designed for photodynamic therapy (PDT) treatment in the near-infrared and for imaging tissue tumors with magnetic resonance imaging (MRI) is reported. It consists of a linear p-conjugated Zn(II)-porphyrin dimer linked at each extremity to a GdDOTA-type complex. This agent has shown very promising potential for PDT applications with good singlet oxygen generation in DMSO and high linear absorption in the near-infrared (lmax= 746 nm, e 105 M-1cm-1). Moreover, this molecule has a propensity for two-photon excited PDT with high two-photon cross-sections (8000 GM in 880-930 nm range), which should allow for deeper tumor treatments and higher spatial precision as compared to conventional one-photon PDT. Regarding the MRI contrast agent properties, the molecule has shown superior relaxivity (14.4 mM-1s-1 at 40 MHz,298 K) in comparison to clinical contrast agents and ability to be internalized in cells, thanks to its amphiphilic character. Irradiation of HeLa cells using either one-photon (740 nm) or two-photon excitation (910 nm) has led in both cases to important cell death. 

Graphical Abstract:


Julie Schmitt, Sébastien Jenni, Angélique Sour, Valérie Heitz, Frédéric Bolze, Agnès Pallier,Célia S. Bonnet, Éva Tóth, and Barbara Ventura

A Porphyrin Dimer-GdDOTA Conjugate as a Theranostic Agent for One- and Two-Photon Photodynamic Therapy and MRI

Bioconjugate Chem., 2018, Article ASAP - DOI: 10.1021/acs.bioconjchem.8b00634

Contact chercheur:

Valérie Heitz (v.heitz@unistra.fr), équipe LSAMM, Institut de Chimie (UMR 7177).